retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing What Is Retatrutide? The Triple

The first demonstration that DPP-4 inhibition reduces blood glucose levels in type 2 diabetes was published in 2002 [36]

Furthermore, the once-weekly exenatide group experienced significantly reduced fasting and postprandial glucose level

doi: 10.1016/j.lfs.2020.118966 195 PetitJMVergsB

Our findings broadly support the advice to discontinue GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation, and also support the ongoing registration of pregnancy outcomes in pharmacological databases since the amount of available data is scarce and mostly limited to animal studies

Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al